Climb Bio (NASDAQ: CLYM) insider transactions
In the twelve months to 10 November 2026, executives and directors of Climb Bio reported 6 open-market sales of 280,902 shares ($2.7m) and 3 open-market purchases of 321,672 shares ($779,626), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 28 September 2026 | Ra Capital Management, L.p. | Director | Option exercise | +10,000 | $3.46 | 10,000 | Form 4 |
| 28 September 2026 | Ra Capital Management, L.p. | Director | Option exercise | +10,000 | $3.00 | 20,000 | Form 4 |
| 28 September 2026 | Ra Capital Management, L.p. | Director | Option exercise | +10,000 | $7.89 | 30,000 | Form 4 |
| 28 September 2026 | Ra Capital Management, L.p. | Director | Option exercise | +40,000 | $1.29 | 70,000 | Form 4 |
| 15 September 2026 | Thomas Stephen Basil | Director | Open-market sale, 10b5-1 plan | −100,000 | $13.67 | 467,969 | Form 4 |
| 29 June 2026 | Brennan Aoife | President and CEO | Open-market sale | −30,902 | $13.17 | 87,731 | Form 4 |
| 27 June 2026 | Brennan Aoife | President and CEO | Option exercise | +68,750 | — | 118,633 | Form 4 |
| 26 February 2026 | Thomas Stephen Basil | Director | Open-market sale | −16,313 | $7.01 | 154,657 | Form 4 |
| 25 February 2026 | Thomas Stephen Basil | Director | Open-market sale | −33,687 | $7.00 | 170,970 | Form 4 |
| 13 February 2026 | Thomas Stephen Basil | Director | Open-market sale | −10,000 | $5.81 | 204,657 | Form 4 |
| 12 February 2026 | Thomas Stephen Basil | Director | Open-market sale | −90,000 | $5.23 | 214,657 | Form 4 |
| 5 January 2026 | RA Capital Healthcare Fund LP | Director | Open-market purchase | +7,111 | $3.50 | 3,403,429 | Form 4 |
| 12 December 2025 | Kolchinsky Peter | Director | Open-market purchase | +101,462 | $2.86 | 3,396,318 | Form 4 |
| 11 December 2025 | Kolchinsky Peter | Director | Returned to the company | −20,440,000 | — | 3,081,757 | Form 4 |
| 11 December 2025 | Kolchinsky Peter | Director | Open-market purchase | +213,099 | $2.18 | 3,294,856 | Form 4 |
| 7 August 2025 | Thomas Stephen Basil | Director | Grant or award | +100,375 | — | 304,657 | Form 4 |
| 30 June 2025 | Brennan Aoife | President and CEO | Open-market sale | −20,618 | $1.22 | 48,132 | Form 4 |
| 27 June 2025 | Thomas Stephen Basil | Director | Option exercise | +25,094 | — | 204,282 | Form 4 |
| 27 June 2025 | Brennan Aoife | President and CEO | Option exercise | +68,750 | — | 68,750 | Form 4 |
| 20 June 2025 | Pimblett Emily | SVP, Finance & CAO | Open-market sale | −1,242 | $1.24 | 18,888 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Climb Bio page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.